- Clinical Trials
- December 2019
- 304 Pages
Global
From €2409EUR$2,500USD£2,072GBP
- Drug Pipelines
- November 2020
- 269 Pages
Global
From €1927EUR$2,000USD£1,658GBP
- Drug Pipelines
- December 2019
- 118 Pages
Global
From €1927EUR$2,000USD£1,658GBP
- Report
- December 2023
- 80 Pages
Global
From €3500EUR$3,891USD£3,116GBP
- Report
- July 2023
- 73 Pages
Global
From €3500EUR$3,891USD£3,116GBP
- Report
- October 2022
- 210 Pages
Global
From €1927EUR$2,000USD£1,658GBP
- Report
- October 2022
- 63 Pages
Global
From €1927EUR$2,000USD£1,658GBP
- Drug Pipelines
- November 2020
- 116 Pages
Global
From €1927EUR$2,000USD£1,658GBP
- Report
- May 2022
- 51 Pages
Global
From €1927EUR$2,000USD£1,658GBP
- Report
- May 2022
- 63 Pages
Global
From €1927EUR$2,000USD£1,658GBP
The Hypercholesterolemia Drug market is a subset of the Cardiovascular Drugs market, which focuses on the treatment of high cholesterol levels. Hypercholesterolemia drugs are used to reduce the amount of cholesterol in the blood, which can help reduce the risk of heart attack and stroke. These drugs are typically prescribed to patients with high cholesterol levels, or those at risk of developing cardiovascular disease. Commonly prescribed drugs include statins, bile acid sequestrants, fibrates, and cholesterol absorption inhibitors.
The Hypercholesterolemia Drug market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include Pfizer, Merck, Sanofi, AstraZeneca, Novartis, and Bristol-Myers Squibb. Show Less Read more